





A high-risk, global equity-only portfolio, dynamically managed

Risk profile

Low

Low-Medium

Medium

Medium-High

High

Investment objective and strategy

The Sygnia Health Innovation Global Equity Fund is a Global–Equity–General portfolio that seeks to deliver long-term capital growth by investing at least 80% of its assets outside of South Africa and being at all times invested in a minimum of 80% equities. The portfolio invests in financially sound equity securities, preference shares that generate capital growth, property shares and property-related assets, fixed income securities and assets in liquid form, be such securities, instruments or assets listed or unlisted financial instruments (derivatives).

Risk profile

The portfolio represents Sygnia's best investment view on the optimal combination of securities required to achieve superior long-term returns at a reasonable level of risk at any time. The portfolio exploits the benefits of diversification and changes its exposure to different securities and sectors on an active basis, according to prevailing market conditions. While aiming to achieve its investment objectives, the portfolio recognises the inevitability of significant short-term volatility and aims to protect capital over the medium to long term.

What the fund invests in

Top 10 Holdings	Percentage	Allocation
Eli Lilly Ord Shs	8.1	
Johnson & Johnson Ord Shs	4.5	
AbbVie Ord Shs	4.0	
UnitedHealth Group Ord Shs	3.5	
Oxford Sciences Innovations PLC (GBP)	3.4	
Novartis Ord Sh	2.9	
Abbott Laboratories Ord Shs	2.8	
Roche Holding Par Shs	2.8	
Novo Nordisk Ord Shs Class B	2.7	
Astrazeneca Ord Shs	2.6	

Who should invest?

Investors seeking currency diversification and higher returns who are willing to tolerate higher volatility and seek to maximise capital accumulation over the longer term through exposure to companies involved in transformative technologies.

Fees

Initial Fees	0.00% (excl. VAT)
Management Fees	0.70% p.a. (excl. VAT)
Other Expenses	0.03% p.a. (excl. VAT)
VAT	0.11%
Total Expense Ratio (TER)	0.85% (Jun 2025)
Transaction Costs (TC)	0.03% (Jun 2025)
Total Investment Charge (TIC)	0.88% (Jun 2025)

Sygnia charges an annual management fee, calculated and accrued daily and payable monthly in arrears. The performance fee is calculated and accrued daily and is deducted monthly. Consequently, the TER of the product may be higher than the annual management fee quoted above

The performance fee is 20% of outperformance of the benchmark, with a cap of 2.30%

Portfolio managers



Kyle HulettCo-Head: Investments
BBusSc (Actuarial), FFA C.Act,
FASSA, CFA



Steven Empedocles Head: Indexation BCom Honours - Financial Risk Management, CFA, FRM

Key facts

Fund Launch Date 5 August 2020

Fund Size R 348 Million

Regulation 28
Non-Compliant

Benchmark

MSCI World Net Total Return Index

Minimum Investment Period

5 years

Disclosures

Sygnia does not provide advice and therefore does not charge advice fees. If a financial planner is appointed, initial and ongoing advice fees may be payable as agreed upon between you and your financial advisor. The payments of these fees are facilitated by the Linked Investment Service Provider (LISP) and not directly by Sygnia. A higher TER does not necessarily imply a poor return, nor does allow TER imply a good return. The current TER may not necessarily be an accurate indication of future TER's. Transaction Costs are a necessary cost in administering the Financial Product and impacts Financial Product returns. It should not be considered in isolation as returns may be impacted by many other factors over time including market returns, the type of Financial Product, the investment decisions of the investment manager and the TER.

Disclaime

SA. Sygnia Collective Investments RF (Pty) Ltd is a registered and approved Manager in Collective Investment Schemes in Securities. Collective investment schemes are generally medium to long-term investments. Sygnia Asset Management (Pty) Limited (FSP 873), an authorised financial services provider, is the appointed investment manager of the Fund. The portfolio may invest in other unit trust portfolios which levy their own fees, and may result in a higher fee structure and that the value of investments / units / unit trusts may go down as well as up. Past performance is not necessarily a guide to future performance. Collective investments are traded at ruling prices and can engage in borrowing and scrip lending. A schedule of fees and charges and maximum commissions is available from the Manager or request. Performance is based on NAV to NAV calculations with it reinvestments done on the ex-div date. Performance is calculated for the portfolio and the individual investor performance may differ as a result of initial fees, actual investment date, date of reinvestment and dividend withholding tax. The Manager does not provide any guarantee either with respect to the capital or the return of a portfolio. Collective investments are calculated on a net asset value basis, which is the total market value of all assets in the portfolio including any income accruals and less any deductible expenses such as audit fees, brokerage and service fees. Forward pricing is used. All the portfolio options presented are approved collective in 2002 ("CISCA"). The fund may from time to time invest in foreign countries and therefore it may have risks regarding liquidity, the repatriation of funds, political and macroeconomic situations, foreign exchange, tax, settlement, and the availability of information. The Manager has the right to close any portfolios to new investors to manage them more efficiently in accordance rith their mandates. A copy of the Minimum Disclosure Document (MDD) is available on our website: www.sygnia.co.za

